Announcements Trials
Browse Landscape

Phase

Phase 3 20Phase 2 9Phase 4 3Phase 1 2

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Other solid neoplasm 1

Conditions

Bone Neoplasms 1Bone Metastasis From Solid Tumors 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × Denosumab × Clear all
NCT04798326 2021-03-15

MW032

Mabwell (Shanghai) Bioscience Co., Ltd.

Phase 1 Completed
120 enrolled
Sarcoma

Bone Neoplasms

NCT04494373 2020-08-04

Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of HS-20090 and Xgeva® in Healthy Adults

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 1 Unknown
154 enrolled
Other solid neoplasm

Bone Metastasis From Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡